- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03190863
Grasping Rehabilitation Using Motor Imagery With or With no Neurofeedback After Tetraplegia (TETRAMINF)
Investigating the Effect of Motor Imagery With or With no Visual Neurofeedback on Grasping Capabilities After C6-C7 Tetraplegia: a Multicentric Randomized Controlled Trial.
Motor imagery has shown promising results to optimize tenodesis grasp in individuals with C6-C7 tetraplegia. However, efficacy of using motor imagery to improve grasping after tetraplegia requires further study with higher level of evidence. In addition, controlling covert practice remains difficult due to the absence of overt movements. However, similar brain activity measured during both over and cover movements makes possible to provide visual information about the covert practice performance using neurofeedback.
The Investigators thus designed this multicentric randomized controlled trial to investigate the effect of motor imagery with or with no visual neurofeedback on grasping capabilities after C6-C7 tetraplegia. They hypothesized that providing neurofeedback based on brain activity measured by electroencephalography namely knowing the covert practice performance would results in greater grasping improvement in response to practice as compared to motor imagery practice alone.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sébastien MATEO, PhD
- Phone Number: +33 478 865 066
- Email: sebastien.mateo@chu-lyon.fr
Study Contact Backup
- Name: Gilles RODE, PhD
- Phone Number: +33 478 865 066
- Email: gilles.rode@chu-lyon.fr
Study Locations
-
-
-
Montpellier, France, 34090
- Recruiting
- Le Centre Mutualiste Neurologique PROPARA, Parc Euromédecine
-
Contact:
- Anthony GELIS, MD
- Email: a.gelis@propara.fr
-
Principal Investigator:
- Anthony GELIS, MD
-
Saint-Genis-Laval, France, 69230
- Recruiting
- Service de médecine physique et de réadaptation, Hôpital Henry Gabrielle
-
Contact:
- Sébastien MATEO
- Email: ext-sebastien.mateo@chu-lyon.fr
-
Principal Investigator:
- Gilles RODE, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Volunteer individuals with C6-C7 tetraplegia with complete finger flexor paralysis restricting grasping capabilities to the tenodesis.
- Consent to participate to the study after receiving clear, loyal and appropriate information.
- Aged between 18 and 55 years.
- Time since spinal cord injury above 6 months
- Stabilized condition in particular sensori-motor deficit.
- Sitting position for more than 1 hour
- Able to imagine movement
- Health care beneficiary
Exclusion Criteria:
- Long-lasting autonomic disorders while sitting (orthostatic hypotension and/or blood pressure instability) limiting sitting position to less than 1 hour.
- Upper limb pain for either mechanic or neuropathic reasons preventing all grasping movement and/or the ability to imagine those movements.
- Restricted wrist and finger range of motion preventing the tenodesis grasp.
- Patient after surgical tendon transfer that improved grasping capabilities (e.g. active finger flexion).
- Ongoing participation in another research that aim to evaluate an intervention likely to improve the neurological or functional recovery introducing an experimental bias.
- Specific contraindication to Magnetoencephalography with the presence of metallic fragments inside the body such as pace-maker, neurostimulator, cochlear implants, steel dental implant and osteosynthesis material only applicable to the participants included in Lyon hospital center (n=15).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motor imagery combined with neurofeedback (MINF)
|
7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement). Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen. |
Active Comparator: Motor imagery (MI)
|
7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants. Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. |
Sham Comparator: Control (C)
|
7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen. Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wrist extension angle in degree during grasping with 3D motion analysis system
Time Frame: Up to 19 weeks
|
Individuals with C6-C7 tetraplegia extend their wrist to grasp using tenodesis.
Specifically, the wrist extension shortens the tendons of fingers and thumbs flexors that elicit either a palmar or a lateral grip.
A complete reach-to-grasp movement will be recorded using a 3D motion analysis system (Vicon Motion Systems Ltd.
UK).
Wrist extension angle in degree will be measure during grasping when the object is grasped.
|
Up to 19 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Temporal kinematic parameters of reach-to-grasp movements with 3D motion analysis system (Vicon Motion Systems Ltd. UK).
Time Frame: Up to 19 weeks
|
Computation of temporal kinematic parameters (e.g.
movement duration) measured during a complete reach-to-grasp movement using a 3D motion analysis system (Vicon Motion Systems Ltd.
UK).
Temporal parameters are also aggregated with spatial parameters.
|
Up to 19 weeks
|
Spatial kinematic parameters of reach-to-grasp movements with 3D motion analysis system (Vicon Motion Systems Ltd. UK).
Time Frame: Up to 19 weeks
|
Computation of spatial kinematic parameters (e.g.
movement trajectory) measured during a complete reach-to-grasp movement using a 3D motion analysis system (Vicon Motion Systems Ltd.
UK).Spatial parameters are also aggregated with temporal parameters.
|
Up to 19 weeks
|
Brain activity change in response to intervention using magnetoencephalography
Time Frame: Up to 19 weeks
|
Brain activity will be measured during upper limb movement (e.g. a complete reach-to-grasp movement) using magnetoencephalography.
The device is only available in Lyon Hospital.
Correspondingly, fifteen participants included in Lyon Hospital will achieve this measure.
|
Up to 19 weeks
|
passive upper limb range of motion (ROM) measured using goniometer and/or inclinometer
Time Frame: Up to 19 weeks
|
This outcome will be measured using goniometer and/or inclinometer by the same blind and experienced physical therapist
|
Up to 19 weeks
|
Upper limb strength measured using the hand held dynamometer
Time Frame: Up to 19 weeks
|
This outcome will be measured using the manual muscle test and the hand held dynamometer by the same blind and experienced physical therapist.
|
Up to 19 weeks
|
Upper limb strength measured using the manual muscle test
Time Frame: Up to 19 weeks
|
This outcome will be measured using the manual muscle test and the hand held dynamometer by the same blind and experienced physical therapist.
|
Up to 19 weeks
|
Hand dexterity measured using the Box and Block test
Time Frame: Up to 19 weeks
|
This outcome will be measured using i) the Box and Block Test, ii) the Nine Hole Peg Test, iii) the Jebsen Test and iv) the Capability of Upper Limb Test supervised by the same blind and experienced occupational therapist
|
Up to 19 weeks
|
Hand dexterity measured using the Nine Hole Peg test
Time Frame: Up to 19 weeks
|
This outcome will be measured using i) the Box and Block Test, ii) the Nine Hole Peg Test, iii) the Jebsen Test and iv) the Capability of Upper Limb Test supervised by the same blind and experienced occupational therapist
|
Up to 19 weeks
|
Hand dexterity measured using the Jebsen test
Time Frame: Up to 19 weeks
|
This outcome will be measured using i) the Box and Block Test, ii) the Nine Hole Peg Test, iii) the Jebsen Test and iv) the Capability of Upper Limb Test supervised by the same blind and experienced occupational therapist
|
Up to 19 weeks
|
Hand dexterity measured using the Capability of Upper Limb test
Time Frame: Up to 19 weeks
|
This outcome will be measured using i) the Box and Block Test, ii) the Nine Hole Peg Test, iii) the Jebsen Test and iv) the Capability of Upper Limb Test supervised by the same blind and experienced occupational therapist
|
Up to 19 weeks
|
Quality of Life measured using the WHOQOL-Bref
Time Frame: Up to 19 weeks
|
This outcome will be measured using the WHOQOL-Bref by the same blind and experienced physical therapist.
|
Up to 19 weeks
|
Daily life autonomy measured using the Quadriplegic Index of Function
Time Frame: Up to 19 weeks
|
This outcome will be measured using the Quadriplegic Index of Function by the same blind and experienced physical therapist.
|
Up to 19 weeks
|
Motor imagery capability measured by the Kinesthetic Visual Imagery Questionnaire
Time Frame: Up to 19 weeks
|
Motor imagery capability will be measured by the Kinesthetic Visual Imagery Questionnaire by the same blind and experienced physical therapist along with comparing overt and covert movement duration, galvanic skin response, electroencephalography activity.
|
Up to 19 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sébastien MATEO, PhD, Hospices Civils de Lyon, Hôpital Henry Gabrielle, Plate-forme Mouvement et Handicap, F-69000 Lyon, France.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL17_0016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will be shared after deidentification (but only the data required for the new analysis will be transmitted). This includes for each visit and each participant averaged data of wrist extension angle during grasping of a single upper limb measured in degree with 3D motion analysis system.
This includes for each visit, each participant and each upper limb:
- Box and Block test
- Nine Hole Peg test
- hand held dynamometer for each of 4 muscles
This includes for each visit and each participant the total score of:
- manual muscle testing of the upper limb key muscles as defined by the ASIA score for each arm
- Capability of Upper Limb
- WHOQOL-Bref
- Quadriplegic Index of Function
- Kinesthetic Visual Imagery Questionnaire This also includes for each visit and each participant the passive range of motion expressed in degree and measured using goniometer for shoulder, elbow and wrist.
This do not include electrophysiological measurements.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Individuals With C6-C7 Tetraplegia (AIS A or B)
-
Novo Nordisk A/SCompletedHaemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BFrance, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
Suzhou Alphamab Co., Ltd.RecruitingHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
-
Novo Nordisk A/SActive, not recruitingHaemophilia A With Inhibitors | Haemophilia B With InhibitorsSpain, Korea, Republic of, India, Australia, United Kingdom, Russian Federation, Poland, Ukraine, Thailand, Mexico, United States, Turkey, Japan, South Africa, Serbia, France, Croatia, Denmark, Algeria, Bulgaria, Malaysia, Portugal, Slovaki... and more
-
AryoGen Pharmed Co.CompletedHemophilia A With Inhibitor | Hemophilia B With InhibitorIran, Islamic Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHemophilia A With Inhibitor | Hemophilia B With InhibitorChina
-
rEVO BiologicsLaboratoire français de Fractionnement et de BiotechnologiesCompletedHemophilia A With Inhibitors | Hemophilia B With InhibitorsUnited States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Clinical Trials on Motor imagery combined with neurofeedback (MINF)
-
National Yang Ming UniversityNot yet recruitingParkinson Disease | Movement Disorder, Functional
-
Kessler FoundationRecruitingStroke | Dyslexia, AcquiredUnited States
-
National Yang Ming UniversityCompletedBiomechanical PhenomenaTaiwan
-
University of TorontoCompleted
-
University of ValenciaAsociación Parkinson ValenciaRecruiting
-
Riphah International UniversityCompleted
-
Riphah International UniversityCompleted
-
Universidad Francisco de VitoriaUniversidad Rey Juan Carlos; Hospital Beata María AnaNot yet recruitingPain | Parkinson DiseaseSpain
-
Prof. Massimo FilippiAzienda Ospedaliera Universitaria Integrata VeronaNot yet recruiting
-
Georgia Institute of TechnologyNational Institute of Neurological Disorders and Stroke (NINDS)Completed